Table 1.
Baseline characteristics of CABG patients.
| Variable | All patients n = 191 | Patients with CPB n = 158 | Patients without CPB n = 33 | p |
|---|---|---|---|---|
| Age (years) | 64.9 ± 8.1 | 65.2 ± 8.2 | 63.5 ± 7.4 | 0.282 |
| Female, n (%) | 43 (22.5) | 35 (22.2) | 8 (24.2) | 0.794 |
| Peripheral vascular disease, n (%) | 31 (16.2) | 25 (15.8) | 6 (18.2) | 0.738 |
| Diabetes mellitus, n (%) | 59 (30.9) | 46 (29.1) | 13 (39.4) | 0.245 |
| Insulin, n (%) | 28 (14.7) | 22 (13.9) | 6 (18.2) | 0.529 |
| Hypertension, n (%) | 158 (82.7) | 127 (80.4) | 31 (93.9) | 0.061 |
| Hypercholesterolemia, n (%) | 126 (66.0) | 101 (63.9) | 25 (75.8) | 0.192 |
| Previous myocardial infarction, n (%) | 154 (80.6) | 128 (81.0) | 26 (78.8) | 0.769 |
| Previous PCI, n (%) | 23 (12.0) | 19 (12.0) | 4 (12.1) | 0.998 |
| Current smoking, n (%) | 54 (34.2) | 44 (32.6) | 10 (43.5) | 0.309 |
| COPD, n (%) | 11 (5.8) | 9 (5.7) | 2 (6.1) | 0.942 |
| Atrial fibrillation, n (%) | 11 (6.8) | 10 (7.2) | 1 (4.3) | 0.610 |
| BMI, kg/m2 | 28.0 ± 3.9 | 28.0 ± 3.9 | 28.0 ± 4.0 | 0.791 |
| LVEF, % | 52.0 ± 9.3 | 52.1 ± 9.4 | 51.3 ± 9.2 | 0.648 |
| EuroSCORE I | 2.9 ± 1.9 | 3.0 ± 1.9 | 2.6 ± 2.0 | 0.329 |
| Aspirin, n (%) | 38 (20.1) | 31 (19.9) | 7 (21.2) | 0.862 |
| ACE inhibitors, n (%) | 168 (88.0) | 137 (86.7) | 31 (93.9) | 0.246 |
| β-blockers, n (%) | 172 (90.1) | 141 (89.2) | 31 (93.9) | 0.412 |
| Lipid-lowering statin, n (%) | 171 (89.5) | 141 (89.2) | 30 (90.9) | 0.776 |
Values are displayed as mean ± standard deviation or number (percentage).
ACE, angiotensin-converting enzyme; BMI, body mass index; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary interventions.